{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://www.pumabiotechnology.com/#organization",
      "name": "Puma Biotechnology, Inc.",
      "url": "https://www.pumabiotechnology.com/",
      "description": "Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Puma has been focused on developing the oral version of nerat"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/puma-biotechnology-inc#asg",
      "name": "Puma Biotechnology, Inc. ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/puma-biotechnology-inc",
      "isPartOf": {
        "@id": "https://www.pumabiotechnology.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}